OncoTarget® Series
When cancer is diagnosed, finding treatment options is the top priority
First FDA-Cleared IVD Comprehensive Genomic Profiling Panel
Available in 6-7 business days
FDA-Cleared (510k) test
Clear insights into therapy options
OncoTarget® 500 integrates the robust bioinformatics of PGDx Elio Tissue Complete and provides physicians and researchers with comprehensive genomic insights for over 500 clinically-relevant genes. FDA-cleared for use in all solid tumors, OncoTarget® 500 harnesses vast genomic data to identify personalized treatment options for each patient.
Learn more